KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Berlin Heidelberg
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/ |